Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone

BackgroundSodium-glucose co-transporter-2 inhibitors (SGLT2i) have cardiovascular (CV) benefits, particularly in reducing the risk of heart failure (HF). Pioglitazone (Pio) has shown potential in decreasing the risks of recurrent stroke, non-fatal myocardial infarction (MI), and all-cause mortality...

全面介紹

書目詳細資料

Principais autores:	Yan-Rong Li, Chih-Ching Wang, Chi-Hung Liu, Chieh-Li Yen, Victor Chien-Chia Wu, Evelyn Jou-Chen Huang, Ching-Yu Lee, Ching-Chung Hsiao
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2024-08-01
叢編:	Frontiers in Endocrinology
主題:	type 2 diabetes mellitus sodium-glucose co-transporter-2 inhibitors (SGLT2i) pioglitazone cardiovascular outcomes heart failure
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1420485/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!